全球个人化医疗生物标记市场规模、份额、趋势和成长分析报告（2026-2034年）

预计个人化医疗生物标记市场将从 2025 年的 266.4 亿美元成长到 2034 年的 982.7 亿美元，2026 年至 2034 年的复合年增长率为 15.61%。

受对标靶性、患者特异性治疗方法的需求不断增长的推动，全球个人化医疗生物标记市场正经历稳步增长。生物标记在识别疾病模式、预测治疗反应和提高诊断准确性方面发挥着至关重要的作用。随着医疗保健系统向精准医疗转型，生物标记在个人化疗法开发中的重要性日益凸显。

基因组学的进步、慢性病病例的增加以及研发投入的加大是推动市场成长的主要因素。製药公司正致力于基于生物标记的药物研发，以提高治疗成功率并减少副作用。此外，政府的支持措施和诊断技术的进步也促进了市场扩张。

未来，分子诊断和人工智慧（AI）领域的创新预计将对市场产生积极影响。随着越来越多的临床试验采用生物标记主导的方法，对可靠且先进的检测解决方案的需求将会增加。个人化医疗的发展趋势将进一步强化生物标记在现代医学中的作用，从而确保市场的长期成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球个人化医疗生物标记市场：依生物标记类型划分

• 市场分析、洞察与预测
• 基因组
• 蛋白质体学
• 代谢
• 其他类型的生物标记

第五章 全球个人化医疗生物标记市场：按应用划分

• 市场分析、洞察与预测
• 早期检测和筛检
• 诊断
• 治疗方案
• 监测
• 其他用途

第六章 全球个人化医疗生物标记市场：依适应症划分

• 市场分析、洞察与预测
• 肿瘤学
• 神经病学
• 糖尿病
• 自体免疫疾病
• 心臟病学
• 其他迹象

第七章 全球个人化医疗生物标记市场：依最终用途划分

• 市场分析、洞察与预测
• 医院和诊所
• 製药和生物技术公司
• 诊断检测实验室
• 其他最终用户

第八章 全球个人化医疗生物标记市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Abbott Laboratories
  • Bio-Rad Laboratories
  • Danaher
  • EKF Diagnostics Holdings
  • F. Hoffmann-La Roche
  • Illumina
  • Lifesign
  • Merck
  • Myriad Genetics
  • Qiagen
  • Signosis
  • Singulex
  • Thermo Fisher Scientific

The Personalized Medicine Biomarkers Market size is expected to reach USD 98.27 Billion in 2034 from USD 26.64 Billion (2025) growing at a CAGR of 15.61% during 2026-2034.

The Global Personalized Medicine Biomarkers Market is experiencing steady growth due to the increasing demand for targeted and patient-specific treatments. Biomarkers play a crucial role in identifying disease patterns, predicting treatment responses, and improving diagnostic accuracy. As healthcare systems move toward precision medicine, the importance of biomarkers in developing personalized therapies is rising significantly.

Growth is mainly driven by advancements in genomics, rising cases of chronic diseases, and increasing investments in research and development. Pharmaceutical companies are focusing on biomarker-based drug development to enhance treatment success rates and reduce side effects. Additionally, supportive government initiatives and improved diagnostic technologies are contributing to market expansion.

In the future, the market is expected to benefit from innovations in molecular diagnostics and artificial intelligence. As more clinical trials adopt biomarker-driven approaches, the demand for reliable and advanced testing solutions will grow. Personalized healthcare trends will continue to strengthen the role of biomarkers in modern medicine, ensuring long-term market growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Biomarker Type

• Genomic
• Proteomics
• Metabolic
• Other Biomarker Types

By Application

• Early Detection/Screening
• Diagnosis
• Treatment Selection
• Monitoring
• Other Applications

By Disease Indication

• Oncology
• Neurology
• Diabetes
• Autoimmune Diseases
• Cardiology
• Other Indications

By End Use

• Hospitals and Clinics
• Pharmaceutical and Biotechnology Companies
• Diagnostic Labs
• Other End Users

COMPANIES PROFILED

• Abbott Laboratories, BioRad Laboratories, Danaher, EKF Diagnostics Holdings, F HoffmannLa Roche, Illumina, Lifesign, Merck, Myriad Genetics, Qiagen, Signosis, Singulex, Thermo Fisher Scientific
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PERSONALIZED MEDICINE BIOMARKERS MARKET: BY BIOMARKER TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Biomarker Type
• 4.2. Genomic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Proteomics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Metabolic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Other Biomarker Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PERSONALIZED MEDICINE BIOMARKERS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Early Detection/Screening Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Diagnosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Treatment Selection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Monitoring Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PERSONALIZED MEDICINE BIOMARKERS MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Disease Indication
• 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Cardiology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Other Indications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PERSONALIZED MEDICINE BIOMARKERS MARKET: BY END USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End Use
• 7.2. Hospitals and Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Pharmaceutical and Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Diagnostic Labs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PERSONALIZED MEDICINE BIOMARKERS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Biomarker Type
  • 8.2.2 By Application
  • 8.2.3 By Disease Indication
  • 8.2.4 By End Use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Biomarker Type
  • 8.3.2 By Application
  • 8.3.3 By Disease Indication
  • 8.3.4 By End Use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Biomarker Type
  • 8.4.2 By Application
  • 8.4.3 By Disease Indication
  • 8.4.4 By End Use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Biomarker Type
  • 8.5.2 By Application
  • 8.5.3 By Disease Indication
  • 8.5.4 By End Use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Biomarker Type
  • 8.6.2 By Application
  • 8.6.3 By Disease Indication
  • 8.6.4 By End Use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PERSONALIZED MEDICINE BIOMARKERS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Abbott Laboratories
  • 10.2.2 Bio-Rad Laboratories
  • 10.2.3 Danaher
  • 10.2.4 EKF Diagnostics Holdings
  • 10.2.5 F. Hoffmann-La Roche
  • 10.2.6 Illumina
  • 10.2.7 Lifesign
  • 10.2.8 Merck
  • 10.2.9 Myriad Genetics
  • 10.2.10 Qiagen
  • 10.2.11 Signosis
  • 10.2.12 Singulex
  • 10.2.13 Thermo Fisher Scientific